J&J strikes its deal with Sail as the in vivo CAR-T space becomes increasingly crowded, with several big pharma players betting on the class.

US efforts to scrutinise overseas drug manufacturing could expose Europe’s role in supplying FDA-approved innovator and biosimilar drugs.

Cell and gene therapy manufacturers are partnering with specialist technology companies to address the challenges associated with scaling complex therapies.

Resilience and Lilly have invested $750m to boost production of Lilly’s KwikPen to boost the US supply of diabetes and obesity medicines.

Specialised Therapeutics’ Niktimvo (axatilimab) was registered in the Australian Register of Therapeutic Goods for later-line cGVHD.

AbbVie's Rinvoq, Pfizer and BioNTech's Comirnaty and Incyte's Opzelura have all received their own EU drug regulatory approvals this week.

Committee members voted 9-3 against recommending approval of Capricor’s deramiocel. Credit: Andrii Yalanskyi/Shutterstock.com. A US Food and Drug Administration (FDA) advisory committee meeting (AdCom ...

Researchers estimate that pharma could unlock up to $1.2tn in commercial value from tropical forests by supporting biodiversity conservation.

Amgen has received a positive opinion from the EMA’s CHMP for Repatha supporting its broader use prior to a first heart attack or stroke.

Synlogic and Caldera Therapeutics have signed a definitive merger agreement aimed at combining in an all-stock transaction.

Dimerix adds DMX-652, a Phase II-ready AKI asset, strengthening its kidney disease pipeline beyond focal segmental glomerulosclerosis (FSGS).

GSK will reallocate a large portion of the £1.9bn saved through to 2029 towards late-stage pipeline acceleration, primarily in oncology.